Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
1136studies shown
Showing 421-432 of 1,136
Drug study icon
CompletedNCT05279313

A study of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

This study is looking at whether Centanafadine Hydrochloride can help people with Attention Deficit/Hyperactivity Disorder. Participants receive a study treatment and complete follow-up visits and assessments.

In Canada
ADHDDrugFrom 4 Years to 18 Years
Countries
United States, Canada
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
ADHD
Behavioral study icon
WithdrawnNCT02476331

A study of Cognitive Training in Euthymic Bipolarity

This study exists to compare options and see whether the medication Cognitive offers something meaningfully different. Researchers are trying to understand whether the medication Cognitive can improve attention, thinking, or day-to-day functioning.

In Canada
BipolarityBehavioralFrom 18 Years to 65 Years
Countries
Canada
Sponsor
University of Calgary
Condition
Bipolarity
Behavioral study icon
CompletedNCT02478827

A study of Cognitive Training in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Canada
SchizophreniaBehavioralFrom 18 Years to 65 Years
Countries
Canada
Sponsor
University of Calgary
Condition
Schizophrenia
Drug study icon
CompletedNCT05593029

A study of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand what a therapy or guided support program could change in day-to-day care and decision-making.

In Canada
DepressionDrugFrom 18 Years to 65 Years
Countries
United States, Canada, Bulgaria, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Depression
Drug study icon
CompletedNCT01323569

Abuse Potential of Sativex

This summary needs review. Please check the official study record and contact the research team for details.

In Canada
AddictionDrugFrom 19 Years to 45 Years
Countries
Canada
Sponsor
Jazz Pharmaceuticals
Condition
Addiction
Device study icon
UnknownNCT06323486

Accelerated Bilateral Sequential Theta Burst Stimulation in Older Adults With Treatment-resistant Depression

This study is looking at care and outcomes for people with depression, Treatment-Resistant. Some participants may receive absTBS-sham treatment sequence arm instead of the study treatment, and direct benefit is not guaranteed.

In Canada
DepressionDeviceA study involving a tool, app, wearable, test, or medical device.Over 50 Years
Countries
Canada
Sponsor
Ontario Shores Centre for Mental Health Sciences
Condition
Depression
Device study icon
CompletedNCT04427137

Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic

This study exists to see whether the medication COVID-19 is workable and worth testing more broadly. Researchers are trying to understand whether the medication COVID-19 can better prevent setbacks and support longer-term stability.

In Canada
Bipolarity, DepressionDeviceOver 18 Years
Countries
Canada
Sponsor
Centre for Addiction and Mental Health
Condition
Bipolarity, Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.